Home > Oncology > ASCO 2022 > Miscellaneous Topics > Ifosfamide is likely to be the go-to therapy in recurrent Ewing sarcoma 

Ifosfamide is likely to be the go-to therapy in recurrent Ewing sarcoma 

Presented By
Dr Martin McCabe, University of Manchester, UK
Conference
ASCO 2022
Trial
Phase 3, rEECur
Doi
https://doi.org/10.55788/b439a2a7
Ifosfamide was more efficacious than topotecan plus cyclophosphamide in patients with primary recurrent or refractory Ewing sarcoma, despite a higher discontinuation rate due to toxicity in the ifosfamide arm. The phase 3 rEECur trial is the first randomised study to deliver efficacy, safety, and quality-of-life data to inform physicians on chemotherapy treatment decisions for patients with recurrent Ewing sarcoma.  No established standard-of-care exists for patients with recurrent/refractory Ewing sarcoma, because there have not been any randomised trials comparing different chemotherapy regimens in this population. Therefore, the phase 3 rEECur trial, presented by Dr Martin McCabe (University of Manchester, UK), randomised patients with previously treated Ewing sarcoma to ifosfamide (n=78) or topotecan plus cyclophosphamide (n=162). The primary...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on